Skip to content

KLRS KLRS Quick ratio

Quick ratio at other companies

Eli Lilly logo
Eli LillyLLY
1.1×0.0×
Merck & Co. logo
Merck & Co.MRK
1.1×-0.2×
Amgen logo
AmgenAMGN
+0.1×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-1.1×
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
6.6×-1.2×
Ocular Therapeutix logo
Ocular TherapeutixOCUL
14.7×+4.6×

Other financials

Income statement

See full
Operating income-$11.8M-14.3%
Net income-$10.9M-6.5%
EPS (diluted)-$0.46+81.7%

Balance sheet

See full
Cash & equivalents$34.4M-65.9%
Total debt$1.4M
Total equity$68.6M+7.3%
Total assets$109.8M+6.5%

Cash flow

See full
Operating cash flow-$11.6M-55.6%
CapEx$17.0K
Free cash flow-$7.1M

Valuation

See full
Market cap$96.83M+136%
Enterprise value$63.82M

Returns & leverage

See full
Return on equity-66.6%
Debt / equity
Current ratio12.2×-2.1×

Where this comes from

Calculated from KLRS’s reported figures.

Based on the most recent quarter.

The official record: KLRS’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about KLRS's quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KLRS's quick ratio?
KLRS (KLRS) reported quick ratio of 12.2× in Q1 2026.
How has KLRS's quick ratio changed year-over-year?
KLRS's quick ratio decreased by 14.8% year-over-year, from 14.3× to 12.2×.
What is the long-term trend for KLRS's quick ratio?
Over 4 years (2021 to 2025), KLRS's quick ratio has grown at a 16.3% compound annual growth rate (CAGR), from 6.7× to 12.2×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.